semaglutide and antipsychotics in Patients With Schizophrenia, Prediabetes, Obesity 🚨 1. Semaglutide significantly improved insulin sensitivity, reduced insulin resistance, lowered fasting glucose, and promoted substantial weight loss in patients with antipsychotic Among patients with #Schizophrenia treated

Energy and mood often improve within a few days

Meet the weight-management clinical criteria (measured at the time GLP-1 therapy was first started): BMI of 35 or higher, or BMI of 30 or higher with heart failure (preserved ejection fraction), uncontrolled high blood pressure, or chronic kidney disease (stage 3a or above), or BMI of 27 or higher with prediabetes, a previous heart attack, a previous stroke, or symptomatic peripheral artery disease

Under the skin injections are less common and can occur in the belly area of the abdomen, fatty areas of the upper thigh or the back of the upper arm

The [elderly] community is very interested in GLP-1, both from the weight loss perspective, but also [when it comes to] the reduction of inflammation, which also seems to drive part of aging

Compound movements (squats, deadlifts, rows, presses) for 3 sets of 8 to 12 reps twice a week is enough

Most patients are advised to maintain a stable weight for several months before pursuing facial surgery, body contouring, or breast procedures